One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients
Check with your clinician if you have cardiovascular disease or major risk factors
PubMed pubmed.ncbi.nlm.nih.gov [41] Semaglutide for the treatment of obesity PubMed pubmed.ncbi.nlm.nih.gov [42] Role of GLP-1 Receptor Agonists in Pediatric Obesity: Benefits, Risks, and Approaches to Patient Selection PubMed pubmed.ncbi.nlm.nih.gov [43] The Antiobesity Effect and Safety of GLP-1 Receptor Agonist in Overweight/Obese Adolescents Without Diabetes Mellitus: A Systematic Review and Meta-Analysis PubMed pubmed.ncbi.nlm.nih.gov [44] A cost comparison of GLP-1 receptor agonists and bariatric surgery: what is the break even point
Recent advances in high-throughput sequencing and metabolomics have elucidated mechanisms linking gut microbiota and associated metabolites to kidney and brain health, revealing the role of microbial diversity and metabolite profiles in disease outcomes
Eckhard U, Schnauer E, Brandstetter H
Khandelwal, M., Manglani, K., Upadhyay, P., Azad, M
